Worldwide Esophageal Cancer Collaboration

pathologic staging data

T. W. Rice, L. Q. Chen, W. L. Hofstetter, B. M. Smithers, V. W. Rusch, B. P L Wijnhoven, K. L. Chen, A. R. Davies, X. B. D'Journo, K. A. Kesler, J. D. Luketich, M. K. Ferguson, J. V. Räsänen, R. van Hillegersberg, W. Fang, L. Durand, I. Cecconello, W. H. Allum, R. J. Cerfolio, M. Pera & 18 others S. M. Griffin, R. Burger, J. F. Liu, M. S. Allen, S. Law, T. J. Watson, G. E. Darling, W. J. Scott, A. Duranceau, C. E. Denlinger, Paul Schipper, T. E M R Lerut, M. B. Orringer, H. Ishwaran, C. Apperson-Hansen, L. M. DiPaola, M. E. Semple, E. H. Blackstone

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0–2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.

    Original languageEnglish (US)
    Pages (from-to)724-733
    Number of pages10
    JournalDiseases of the Esophagus
    Volume29
    Issue number7
    DOIs
    StatePublished - Oct 1 2016

    Fingerprint

    Esophageal Neoplasms
    Squamous Cell Carcinoma
    Adenocarcinoma
    Neoplasm Staging
    Neoplasms
    Survival
    Adenosquamous Carcinoma
    Risk Adjustment
    Esophagogastric Junction
    Esophagus
    Comorbidity
    Weight Loss
    Body Mass Index
    Smoking
    Demography
    Carcinoma
    Mortality
    Therapeutics

    Keywords

    • cancer staging
    • decision-making
    • esophagectomy
    • prognostication
    • survival

    ASJC Scopus subject areas

    • Gastroenterology

    Cite this

    Rice, T. W., Chen, L. Q., Hofstetter, W. L., Smithers, B. M., Rusch, V. W., Wijnhoven, B. P. L., ... Blackstone, E. H. (2016). Worldwide Esophageal Cancer Collaboration: pathologic staging data. Diseases of the Esophagus, 29(7), 724-733. https://doi.org/10.1111/dote.12520

    Worldwide Esophageal Cancer Collaboration : pathologic staging data. / Rice, T. W.; Chen, L. Q.; Hofstetter, W. L.; Smithers, B. M.; Rusch, V. W.; Wijnhoven, B. P L; Chen, K. L.; Davies, A. R.; D'Journo, X. B.; Kesler, K. A.; Luketich, J. D.; Ferguson, M. K.; Räsänen, J. V.; van Hillegersberg, R.; Fang, W.; Durand, L.; Cecconello, I.; Allum, W. H.; Cerfolio, R. J.; Pera, M.; Griffin, S. M.; Burger, R.; Liu, J. F.; Allen, M. S.; Law, S.; Watson, T. J.; Darling, G. E.; Scott, W. J.; Duranceau, A.; Denlinger, C. E.; Schipper, Paul; Lerut, T. E M R; Orringer, M. B.; Ishwaran, H.; Apperson-Hansen, C.; DiPaola, L. M.; Semple, M. E.; Blackstone, E. H.

    In: Diseases of the Esophagus, Vol. 29, No. 7, 01.10.2016, p. 724-733.

    Research output: Contribution to journalArticle

    Rice, TW, Chen, LQ, Hofstetter, WL, Smithers, BM, Rusch, VW, Wijnhoven, BPL, Chen, KL, Davies, AR, D'Journo, XB, Kesler, KA, Luketich, JD, Ferguson, MK, Räsänen, JV, van Hillegersberg, R, Fang, W, Durand, L, Cecconello, I, Allum, WH, Cerfolio, RJ, Pera, M, Griffin, SM, Burger, R, Liu, JF, Allen, MS, Law, S, Watson, TJ, Darling, GE, Scott, WJ, Duranceau, A, Denlinger, CE, Schipper, P, Lerut, TEMR, Orringer, MB, Ishwaran, H, Apperson-Hansen, C, DiPaola, LM, Semple, ME & Blackstone, EH 2016, 'Worldwide Esophageal Cancer Collaboration: pathologic staging data', Diseases of the Esophagus, vol. 29, no. 7, pp. 724-733. https://doi.org/10.1111/dote.12520
    Rice TW, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, Wijnhoven BPL et al. Worldwide Esophageal Cancer Collaboration: pathologic staging data. Diseases of the Esophagus. 2016 Oct 1;29(7):724-733. https://doi.org/10.1111/dote.12520
    Rice, T. W. ; Chen, L. Q. ; Hofstetter, W. L. ; Smithers, B. M. ; Rusch, V. W. ; Wijnhoven, B. P L ; Chen, K. L. ; Davies, A. R. ; D'Journo, X. B. ; Kesler, K. A. ; Luketich, J. D. ; Ferguson, M. K. ; Räsänen, J. V. ; van Hillegersberg, R. ; Fang, W. ; Durand, L. ; Cecconello, I. ; Allum, W. H. ; Cerfolio, R. J. ; Pera, M. ; Griffin, S. M. ; Burger, R. ; Liu, J. F. ; Allen, M. S. ; Law, S. ; Watson, T. J. ; Darling, G. E. ; Scott, W. J. ; Duranceau, A. ; Denlinger, C. E. ; Schipper, Paul ; Lerut, T. E M R ; Orringer, M. B. ; Ishwaran, H. ; Apperson-Hansen, C. ; DiPaola, L. M. ; Semple, M. E. ; Blackstone, E. H. / Worldwide Esophageal Cancer Collaboration : pathologic staging data. In: Diseases of the Esophagus. 2016 ; Vol. 29, No. 7. pp. 724-733.
    @article{3d661582200749f69db046dbaa4d4a50,
    title = "Worldwide Esophageal Cancer Collaboration: pathologic staging data",
    abstract = "We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80{\%}) with normal body mass index (51{\%}), little weight loss (1.8 kg), 0–2 ECOG performance status (83{\%}), and a history of smoking (70{\%}). Cancers were pT1 (24{\%}), pT2 (15{\%}), pT3 (50{\%}), pN0 (52{\%}), pM0 (93{\%}), and pG2-G3 (78{\%}); most involved distal esophagus (71{\%}). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.",
    keywords = "cancer staging, decision-making, esophagectomy, prognostication, survival",
    author = "Rice, {T. W.} and Chen, {L. Q.} and Hofstetter, {W. L.} and Smithers, {B. M.} and Rusch, {V. W.} and Wijnhoven, {B. P L} and Chen, {K. L.} and Davies, {A. R.} and D'Journo, {X. B.} and Kesler, {K. A.} and Luketich, {J. D.} and Ferguson, {M. K.} and R{\"a}s{\"a}nen, {J. V.} and {van Hillegersberg}, R. and W. Fang and L. Durand and I. Cecconello and Allum, {W. H.} and Cerfolio, {R. J.} and M. Pera and Griffin, {S. M.} and R. Burger and Liu, {J. F.} and Allen, {M. S.} and S. Law and Watson, {T. J.} and Darling, {G. E.} and Scott, {W. J.} and A. Duranceau and Denlinger, {C. E.} and Paul Schipper and Lerut, {T. E M R} and Orringer, {M. B.} and H. Ishwaran and C. Apperson-Hansen and DiPaola, {L. M.} and Semple, {M. E.} and Blackstone, {E. H.}",
    year = "2016",
    month = "10",
    day = "1",
    doi = "10.1111/dote.12520",
    language = "English (US)",
    volume = "29",
    pages = "724--733",
    journal = "Diseases of the Esophagus",
    issn = "1120-8694",
    publisher = "Wiley-Blackwell",
    number = "7",

    }

    TY - JOUR

    T1 - Worldwide Esophageal Cancer Collaboration

    T2 - pathologic staging data

    AU - Rice, T. W.

    AU - Chen, L. Q.

    AU - Hofstetter, W. L.

    AU - Smithers, B. M.

    AU - Rusch, V. W.

    AU - Wijnhoven, B. P L

    AU - Chen, K. L.

    AU - Davies, A. R.

    AU - D'Journo, X. B.

    AU - Kesler, K. A.

    AU - Luketich, J. D.

    AU - Ferguson, M. K.

    AU - Räsänen, J. V.

    AU - van Hillegersberg, R.

    AU - Fang, W.

    AU - Durand, L.

    AU - Cecconello, I.

    AU - Allum, W. H.

    AU - Cerfolio, R. J.

    AU - Pera, M.

    AU - Griffin, S. M.

    AU - Burger, R.

    AU - Liu, J. F.

    AU - Allen, M. S.

    AU - Law, S.

    AU - Watson, T. J.

    AU - Darling, G. E.

    AU - Scott, W. J.

    AU - Duranceau, A.

    AU - Denlinger, C. E.

    AU - Schipper, Paul

    AU - Lerut, T. E M R

    AU - Orringer, M. B.

    AU - Ishwaran, H.

    AU - Apperson-Hansen, C.

    AU - DiPaola, L. M.

    AU - Semple, M. E.

    AU - Blackstone, E. H.

    PY - 2016/10/1

    Y1 - 2016/10/1

    N2 - We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0–2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.

    AB - We report data—simple descriptions of patient characteristics, cancer categories, and non–risk-adjusted survival—for patients with pathologically staged cancer of the esophagus and esophagogastric junction after resection or ablation with no preoperative therapy from the Worldwide Esophageal Cancer Collaboration (WECC). Thirty-three institutions from six continents submitted de-identified data using standard definitions: demographics, comorbidities, clinical cancer categories, and all-cause mortality from first management decision. Of 13,300 patients, 5,631 had squamous cell carcinoma, 7,558 adenocarcinoma, 85 adenosquamous carcinoma, and 26 undifferentiated carcinoma. Patients were older (62 years) men (80%) with normal body mass index (51%), little weight loss (1.8 kg), 0–2 ECOG performance status (83%), and a history of smoking (70%). Cancers were pT1 (24%), pT2 (15%), pT3 (50%), pN0 (52%), pM0 (93%), and pG2-G3 (78%); most involved distal esophagus (71%). Non–risk-adjusted survival for both squamous cell carcinoma and adenocarcinoma was monotonic and distinctive across pTNM. Survival was more distinctive for adenocarcinoma than squamous cell carcinoma when pT was ordered by pN. Survival for pTis-1 adenocarcinoma was better than for squamous cell carcinoma, although monotonic and distinctive for both. WECC pathologic staging data is improved over that of the 7th edition, with more patients studied and patient and cancer variables collected. These data will be the basis for the 8th edition cancer staging manuals following risk adjustment for patient, cancer, and treatment characteristics, and should direct 9th edition data collection. However, the role of pure pathologic staging as the principal point of reference for esophageal cancer staging is waning.

    KW - cancer staging

    KW - decision-making

    KW - esophagectomy

    KW - prognostication

    KW - survival

    UR - http://www.scopus.com/inward/record.url?scp=84991112574&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84991112574&partnerID=8YFLogxK

    U2 - 10.1111/dote.12520

    DO - 10.1111/dote.12520

    M3 - Article

    VL - 29

    SP - 724

    EP - 733

    JO - Diseases of the Esophagus

    JF - Diseases of the Esophagus

    SN - 1120-8694

    IS - 7

    ER -